FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366353507> ?p ?o ?g. }

• W4366353507 endingPage "2156" @default.
• W4366353507 startingPage "2148" @default.
• W4366353507 abstract "Abstract Background Previous research has shown greater efficacy of dupilumab in patients with uncontrolled asthma and type 2 inflammation. We analyzed dupilumab's efficacy in patients from the TRAVERSE study with or without evidence of allergic asthma and type 2 inflammation per current GINA guidelines (≥150 eosinophils/μL or FeNO ≥20 ppb). Methods All patients aged ≥12 years who rolled over from the placebo‐controlled QUEST study (NCT02414854) to TRAVERSE (NCT02134028) received add‐on dupilumab 300 mg every 2 weeks for up to 96 weeks. We assessed annualized severe asthma exacerbation rates (AERs) and changes from parent‐study baseline (PSBL) in pre‐bronchodilator FEV 1 and 5‐item asthma control questionnaire (ACQ‐5) score in patients with moderate‐to‐severe type 2 asthma with and without evidence of allergic asthma at PSBL. Results In TRAVERSE, dupilumab consistently reduced AER across all subgroups. By Week 96, dupilumab increased pre‐bronchodilator FEV 1 from PSBL by 0.35–0.41 L in patients receiving placebo during QUEST (placebo/dupilumab) and 0.34–0.44 L in those receiving dupilumab during QUEST (dupilumab/dupilumab) with an allergic phenotype at baseline. In patients without evidence of allergic asthma, pre‐bronchodilator FEV 1 improved by 0.38–0.41 L and 0.33–0.37 L, respectively. By Week 48, ACQ‐5 scores decreased from PSBL by 1.63–1.69 (placebo/dupilumab) and 1.74–1.81 (dupilumab/dupilumab) points across subgroups with allergic asthma, and 1.75–1.83 (placebo/dupilumab) and 1.78–1.86 (dupilumab/dupilumab) in those without. Conclusions Long‐term treatment with dupilumab reduced exacerbation rates and improved lung function and asthma control in patients with asthma with type 2 inflammation as per current GINA guidance and irrespective of evidence of allergic asthma." @default.
• W4366353507 created "2023-04-21" @default.
• W4366353507 creator A5011255987 @default.
• W4366353507 creator A5017711682 @default.
• W4366353507 creator A5024974445 @default.
• W4366353507 creator A5028265360 @default.
• W4366353507 creator A5037227971 @default.
• W4366353507 creator A5037945336 @default.
• W4366353507 creator A5039293124 @default.
• W4366353507 creator A5043657394 @default.
• W4366353507 creator A5044980958 @default.
• W4366353507 creator A5051113472 @default.
• W4366353507 creator A5059328493 @default.
• W4366353507 creator A5069220861 @default.
• W4366353507 date "2023-05-21" @default.
• W4366353507 modified "2023-10-14" @default.
• W4366353507 title "Dupilumab improves long‐term outcomes in patients with uncontrolled, <scp>moderate‐to‐severe GINA‐based</scp> type 2 asthma, irrespective of allergic status" @default.
• W4366353507 cites W1997702790 @default.
• W4366353507 cites W2000650705 @default.
• W4366353507 cites W2039439214 @default.
• W4366353507 cites W2061435251 @default.
• W4366353507 cites W2061775758 @default.
• W4366353507 cites W2101401558 @default.
• W4366353507 cites W2105521580 @default.
• W4366353507 cites W2342693354 @default.
• W4366353507 cites W2594033175 @default.
• W4366353507 cites W2803941918 @default.
• W4366353507 cites W2805002966 @default.
• W4366353507 cites W2972864777 @default.
• W4366353507 cites W2996174934 @default.
• W4366353507 cites W4226321823 @default.
• W4366353507 cites W4292737569 @default.
• W4366353507 cites W4308770808 @default.
• W4366353507 cites W4312181912 @default.
• W4366353507 cites W4319075002 @default.
• W4366353507 doi "https://doi.org/10.1111/all.15747" @default.
• W4366353507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37073882" @default.
• W4366353507 hasPublicationYear "2023" @default.
• W4366353507 type Work @default.
• W4366353507 citedByCount "1" @default.
• W4366353507 countsByYear W43663535072023 @default.
• W4366353507 crossrefType "journal-article" @default.
• W4366353507 hasAuthorship W4366353507A5011255987 @default.
• W4366353507 hasAuthorship W4366353507A5017711682 @default.
• W4366353507 hasAuthorship W4366353507A5024974445 @default.
• W4366353507 hasAuthorship W4366353507A5028265360 @default.
• W4366353507 hasAuthorship W4366353507A5037227971 @default.
• W4366353507 hasAuthorship W4366353507A5037945336 @default.
• W4366353507 hasAuthorship W4366353507A5039293124 @default.
• W4366353507 hasAuthorship W4366353507A5043657394 @default.
• W4366353507 hasAuthorship W4366353507A5044980958 @default.
• W4366353507 hasAuthorship W4366353507A5051113472 @default.
• W4366353507 hasAuthorship W4366353507A5059328493 @default.
• W4366353507 hasAuthorship W4366353507A5069220861 @default.
• W4366353507 hasBestOaLocation W43663535071 @default.
• W4366353507 hasConcept C126322002 @default.
• W4366353507 hasConcept C142724271 @default.
• W4366353507 hasConcept C203014093 @default.
• W4366353507 hasConcept C204787440 @default.
• W4366353507 hasConcept C207480886 @default.
• W4366353507 hasConcept C27081682 @default.
• W4366353507 hasConcept C2776042228 @default.
• W4366353507 hasConcept C2777014857 @default.
• W4366353507 hasConcept C2778329239 @default.
• W4366353507 hasConcept C2778391694 @default.
• W4366353507 hasConcept C2779824493 @default.
• W4366353507 hasConcept C2780510475 @default.
• W4366353507 hasConcept C2781018748 @default.
• W4366353507 hasConcept C71924100 @default.
• W4366353507 hasConcept C90924648 @default.
• W4366353507 hasConceptScore W4366353507C126322002 @default.
• W4366353507 hasConceptScore W4366353507C142724271 @default.
• W4366353507 hasConceptScore W4366353507C203014093 @default.
• W4366353507 hasConceptScore W4366353507C204787440 @default.
• W4366353507 hasConceptScore W4366353507C207480886 @default.
• W4366353507 hasConceptScore W4366353507C27081682 @default.
• W4366353507 hasConceptScore W4366353507C2776042228 @default.
• W4366353507 hasConceptScore W4366353507C2777014857 @default.
• W4366353507 hasConceptScore W4366353507C2778329239 @default.
• W4366353507 hasConceptScore W4366353507C2778391694 @default.
• W4366353507 hasConceptScore W4366353507C2779824493 @default.
• W4366353507 hasConceptScore W4366353507C2780510475 @default.
• W4366353507 hasConceptScore W4366353507C2781018748 @default.
• W4366353507 hasConceptScore W4366353507C71924100 @default.
• W4366353507 hasConceptScore W4366353507C90924648 @default.
• W4366353507 hasFunder F4320307781 @default.
• W4366353507 hasIssue "8" @default.
• W4366353507 hasLocation W43663535071 @default.
• W4366353507 hasLocation W43663535072 @default.
• W4366353507 hasOpenAccess W4366353507 @default.
• W4366353507 hasPrimaryLocation W43663535071 @default.
• W4366353507 hasRelatedWork W2418399628 @default.
• W4366353507 hasRelatedWork W2901676388 @default.
• W4366353507 hasRelatedWork W3010474792 @default.
• W4366353507 hasRelatedWork W3179356691 @default.
• W4366353507 hasRelatedWork W3214108187 @default.
• W4366353507 hasRelatedWork W4210339708 @default.
• W4366353507 hasRelatedWork W4308903353 @default.

• next